Answers are grounded in this paper and cite their sources.
Background: Donor-derived cell-free DNA (ddcfDNA) and gene expression profiling (GEP) allow for non-invasive monitoring of rejection after heart transplantation in place of endomyocardial biopsies (EMBx). However, data are limited on the impact this strategy has on heart transplant graft outcomes after 2 years post transplant. Methods: This is a single center, retrospective analysis of adult heart transplant recipients, comparing a rejection surveillance cohort of GEP/biopsy (1/2015-12/2017) against a rejection surveillance cohort of GEP/ddcfDNA (7/2018-12/2020). The primary outcome was survival at 3 years post transplant. Secondary outcomes included ejection fraction (EF), rejection free survival, total number of EMBx in follow-up period, and development of de novo donor specific antibodies (dnDSA). Results: A total of 88 patients in the GEP/Biopsy cohort and 90 patients in the GEP/ddcfDNA cohort were included in the analysis. When comparing GEP/Biopsy against GEP/ddcfDNA, overall survival (85.2% vs. 86.7%, p=0.78). Biopsy proven acute cellular rejection (70.5% vs 83.3%, p = 0.062), biopsy proven antibody mediated rejection (97.7 vs. 94.5%, p = 0.26), LVEF at 3 years [60.3 (57.9-63.6) vs. 60.3 (57.5-63.1], and development of dnDSA [34/88 (38.6%) vs. 36/91 (39.6%), p = 1.0] when comparing GEP/biopsy against GEP/ddcfDNA, indicating similar clinical outcomes. However, patients in the GEP/ddcfDNA had fewer biopsies [4 (3-6) vs. 12 (10-14), p<0.001)]. Conclusions: When comparing a rejection surveillance strategy of GEP/biopsy against GEP/ddcfDNA, heart transplant outcomes were similar at 3 years, while a strategy of GEP/ddcfDNA resulted in significantly fewer EMBx.
No takes yet. Share an insight, caveat, or question.
Henricksen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: